Nicholas James Short MD

Hematologic Oncology

Fellow in Hematology/Oncology, University of Texas MD Anderson Cancer Center

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Short is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Short's full profile Already have an account?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
Baylor College of MedicineClass of 2011

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2026 - Present
TN State Medical License 2026 - 2029
GA State Medical License 2026 - 2028
AZ State Medical License 2026 - 2027
LA State Medical License 2026 - 2027
MS State Medical License 2026 - 2027
OK State Medical License 2020 - 2027
TX State Medical License 2014 - 2027
AL State Medical License 2026 - 2026
MA State Medical License 2013 - 2015
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Inductee Alpha Omega Alpha Honor Medical Society, 2011

Clinical Trials

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2019 Feb 27
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Start of enrollment: 2020 May 17
COMPLETED
PHASE2
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies Start of enrollment: 2020 Nov 06
RECRUITING
PHASE1, PHASE2

Publications & Presentations

PubMed

Treatment of older adults with newly diagnosed-mutated AML: focus on lower-intensity triplet regimens.
Sankalp Arora, Naval Daver, Farhad Ravandi, Nicholas J Short
Expert Review of Hematology. 2026-08-18
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.
Aziz Farhat, Georgina El Hajjar, Hagop Kantarjian, Koji Sasaki, Nicholas J Short
Cancer. 2026-08-15
Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.
Sankalp Arora, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Zhouxuan Li
American Journal of Hematology. 2026-08-01

Abstracts/Posters

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD NegativityDecember 23rd, 2024
Research Reveals How Fructose in Diet Enhances Tumor GrowthDecember 4th, 2024
MD Anderson Research Highlights: ASH 2024 Special EditionDecember 4th, 2024